Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2023 11:01 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Quarter of 2023

May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights Genmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million “In...
April 24, 2023 04:39 ET | Source: Genmab A/S

Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen

Company Announcement COPENHAGEN, Denmark; April 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second...
April 20, 2023 19:45 ET | Source: Genmab A/S

Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen

Company Announcement COPENHAGEN, Denmark; April 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc....
April 18, 2023 06:25 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023

Company Announcement Net sales of DARZALEX® in the first quarter of 2023 totaled USD 2,264 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
April 17, 2023 02:00 ET | Source: Genmab A/S

Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

Media ReleaseCOPENHAGEN, Denmark; April 17, 2023 Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody...
April 06, 2023 16:33 ET | Source: Genmab A/S

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; April 6, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
April 03, 2023 16:30 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; April 3, 2023 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
April 03, 2023 10:12 ET | Source: Genmab A/S

Completion of share buy-back program

Company Announcement COPENHAGEN, Denmark; April 3, 2023 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 31, 2023. On February 22, 2023, Genmab...
March 29, 2023 16:19 ET | Source: Genmab A/S

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
March 29, 2023 16:10 ET | Source: Genmab A/S

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to...